A BILL 
To limit the price of insulin drugs accessible for participants, 
beneficiaries, and enrollees enrolled in group or individual 
health insurance coverage and group health plans and 
for uninsured individuals who have diabetes, and for 
other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Matt’s Act’’. 
4
01:44 Aug 10, 2021
H4813
2 
•HR 4813 IH
SEC. 2. INSULIN NET PRICE PROTECTION. 
1
(a) PUBLISHING OF NET PRICE BY MANUFACTUR-
2
ERS.— 
3
(1) IN GENERAL.—A manufacturer of an insu-
4
lin drug shall, on a quarterly basis, publish on the 
5
internet website of such manufacturer the average 
6
net price of each such insulin drug for the preceding 
7
calendar quarter. 
8
(2) ENFORCEMENT.—In the case that a manu-
9
facturer of an insulin drug fails to comply with para-
10
graph (1), a Federal agency or program may not 
11
make payment for such insulin drug of such until 
12
such manufacturer complies with such paragraph. 
13
(b) NET PRICE FOR INSULIN DRUGS FOR CERTAIN 
14
INDIVIDUALS.— 
15
(1) APPLICATION TO PHSA PLANS.—Subpart 1 
16
of part A of the Public Health Service Act (42 
17
U.S.C. 300gg et seq.) is amended by adding at the 
18
end the following new section: 
19
‘‘SEC. 2730. NET PRICE FOR INSULIN DRUGS. 
20
‘‘(a) AVAILABILITY OF NET PRICE.—With respect to 
21
plan years beginning on and after January 1, 2022, a 
22
health insurance issuer offering group or individual health 
23
insurance coverage shall provide a participant, beneficiary, 
24
or enrollee who has diabetes access to an insulin drug at— 
25
‘‘(1) the lesser of— 
26
01:44 Aug 10, 2021
H4813
3 
•HR 4813 IH
‘‘(A) the 10 percent of the average net 
1
price for such drug published pursuant to sec-
2
tion 2(a) of Matt’s Act, plus the average 
3
charges for distribution and dispensing de-
4
scribed in subsection (c) for such drug; 
5
‘‘(B) the coinsurance amount for an insu-
6
lin drug under the health insurance coverage 
7
under which such an individual is a participant, 
8
beneficiary, or enrollee would otherwise be re-
9
sponsible notwithstanding this section; or 
10
‘‘(C) $20; or 
11
‘‘(2) $0, in the case such a participant, bene-
12
ficiary, or enrollee is enrolled in a high deductible 
13
health plan (as defined in section 223(c)(2) of the 
14
Internal Revenue Code of 1986). 
15
‘‘(b) WAIVER OF DEDUCTIBLE.—In applying sub-
16
section (a), such a participant, beneficiary, or enrollee 
17
shall have access to an insulin drug without regard to a 
18
deductible. 
19
‘‘(c) CHARGES
FOR
DISTRIBUTING
AND
DIS-
20
PENSING.— 
21
‘‘(1) IN GENERAL.—For purposes of subsection 
22
(a), charges for distribution and dispensing de-
23
scribed in this subsection— 
24
01:44 Aug 10, 2021
H4813
4 
•HR 4813 IH
‘‘(A) are charges associated with the trans-
1
actions, with respect to an insulin drug, be-
2
tween wholesalers, distributors, retailers, and 
3
pharmacies; and 
4
‘‘(B) may not exceed 10 percent of the av-
5
erage net price of such an insulin drug. 
6
‘‘(2) REPORTING REQUIREMENT FOR PLANS.— 
7
In the case that a health insurance issuer offering 
8
group or individual health insurance coverage 
9
charges a participant, beneficiary, or enrollee for av-
10
erage charges for distribution and dispensing pursu-
11
ant to subsection (a)(1), the health insurance issuer 
12
shall submit to the Inspector General of the Depart-
13
ment of Health and Human Services information 
14
with respect to such charges and the amount of the 
15
charges. 
16
‘‘(3) REPORT
TO
CONGRESS
BY
INSPECTOR 
17
GENERAL.—Beginning January 1, 2023, and annu-
18
ally thereafter, the Inspector General shall review 
19
the charges described in paragraph (2) and submit 
20
to Congress a report on such on review. 
21
‘‘(d) DEFINITIONS.—In this section: 
22
‘‘(1) INSULIN.— 
23
‘‘(A) IN
GENERAL.—The term ‘insulin’ 
24
means a prescription drug containing insulin 
25
01:44 Aug 10, 2021
H4813
5 
•HR 4813 IH
that is approved by the Food and Drug Admin-
1
istration to improve glycemic control in patients 
2
with diabetes mellitus (and may include any 
3
medical supplies included with such drug or as-
4
sociated with the injection of such drug). 
5
‘‘(B) EXCLUSION.—Such term does not in-
6
clude any medical supplies that provides for the 
7
monitoring of insulin levels. 
8
‘‘(2) LIST PRICE.—The term ‘list price’ has the 
9
meaning given the term wholesale acquisition cost in 
10
section 1847A(c)(6)(B) of the Social Security Act. 
11
‘‘(3) NET PRICE.—The term ‘net price’ means, 
12
with respect to prescription drug coverage under 
13
group or individual health insurance coverage of-
14
fered by a health insurance issuer, the list price of 
15
the drug net all rebates, discounts, concessions, and 
16
other adjustments applied to the cost paid by the 
17
health insurance issuer, or by any other entity that 
18
provides pharmacy benefit management services 
19
under a contract with any such health insurance 
20
issuer, regardless of whether such adjustments are 
21
prospective or retrospective. 
22
‘‘(4) PRESCRIPTION
DRUG.—The term ‘pre-
23
scription drug’ mean a drug, as defined in section 
24
201(g) of the Federal Food, Drug, and Cosmetic 
25
01:44 Aug 10, 2021
H4813
6 
•HR 4813 IH
Act, that is subject to section 503(b)(1) of such 
1
Act.’’. 
2
(2) APPLICATION TO ERISA PLANS.—Subpart A 
3
of part 7 of the Employee Retirement Income Secu-
4
rity Act of 1974 (29 U.S.C. 1185 et seq.) is amend-
5
ed by adding at the end the following new section 
6
(and amending the table of contents accordingly): 
7
‘‘SEC. 704. NET PRICE FOR INSULIN DRUGS. 
8
‘‘(a) AVAILABILITY OF NET PRICE.—With respect to 
9
plan years beginning on and after January 1, 2022, a 
10
group health plan shall provide a participant, beneficiary, 
11
or enrollee who has diabetes access to an insulin drug at— 
12
‘‘(1) the lesser of— 
13
‘‘(A) the 10 percent of the average net 
14
price for such drug published pursuant to sec-
15
tion 2(a) of Matt’s Act, plus the average 
16
charges for distribution and dispensing de-
17
scribed in subsection (c) for such drug; 
18
‘‘(B) the coinsurance amount for an insu-
19
lin drug under the group health plan which 
20
such an individual is a participant, beneficiary, 
21
or enrollee would otherwise be responsible not-
22
withstanding this section; or 
23
‘‘(C) $20; or 
24
01:44 Aug 10, 2021
H4813
7 
•HR 4813 IH
‘‘(2) $0, in the case such a participant, bene-
1
ficiary, or enrollee is enrolled in a high deductible 
2
health plan (as defined in section 223(c)(2) of the 
3
Internal Revenue Code of 1986). 
4
‘‘(b) WAIVER OF DEDUCTIBLE.—In applying sub-
5
section (a), such a participant, beneficiary, or enrollee 
6
shall have access to an insulin drug without regard to a 
7
deductible. 
8
‘‘(c) CHARGES
FOR
DISTRIBUTING
AND
DIS-
9
PENSING.— 
10
‘‘(1) IN GENERAL.—For purposes of subsection 
11
(a), charges for distribution and dispensing de-
12
scribed in this subsection— 
13
‘‘(A) are charges associated with the trans-
14
actions, with respect to an insulin drug, be-
15
tween wholesalers, distributors, retailers, and 
16
pharmacies; and 
17
‘‘(B) may not exceed 10 percent of the av-
18
erage net price of such an insulin drug. 
19
‘‘(2) REPORTING REQUIREMENT FOR PLANS.— 
20
In the case that a group health plan charges a par-
21
ticipant, beneficiary, or enrollee for average charges 
22
for distribution and dispensing pursuant to sub-
23
section (a)(1), the group health plan shall submit to 
24
the Inspector General of the Department of Health 
25
01:44 Aug 10, 2021
H4813
8 
•HR 4813 IH
and Human Services information with respect to 
1
such charges and the amount of the charges. 
2
‘‘(3) REPORT
TO
CONGRESS
BY
INSPECTOR 
3
GENERAL.—Beginning January 1, 2023, and annu-
4
ally thereafter, the Inspector General shall review 
5
the charges described in paragraph (2) and submit 
6
to Congress a report on such on review. 
7
‘‘(d) DEFINITIONS.—In this section: 
8
‘‘(1) INSULIN.— 
9
‘‘(A) IN
GENERAL.—The term ‘insulin’ 
10
means a prescription drug containing insulin 
11
that is approved by the Food and Drug Admin-
12
istration to improve glycemic control in patients 
13
with diabetes mellitus (and may include any 
14
medical supplies included with such drug or as-
15
sociated with the injection of such drug). 
16
‘‘(B) EXCLUSION.—Such term does not in-
17
clude any medical supplies that provides for the 
18
monitoring of insulin levels. 
19
‘‘(2) LIST PRICE.—The term ‘list price’ has the 
20
meaning given the term wholesale acquisition cost in 
21
section 1847A(c)(6)(B) of the Social Security Act. 
22
‘‘(3) NET PRICE.—The term ‘net price’ means, 
23
with respect to prescription drug coverage under a 
24
group health plan , the list price of the drug net all 
25
01:44 Aug 10, 2021
H4813
9 
•HR 4813 IH
rebates, discounts, concessions, and other adjust-
1
ments applied to the cost paid by the group health 
2
plan, or by any other entity that provides pharmacy 
3
benefit management services under a contract with 
4
any such group health plan, regardless of whether 
5
such adjustments are prospective or retrospective. 
6
‘‘(4) PRESCRIPTION
DRUG.—The term ‘pre-
7
scription drug’ mean a drug, as defined in section 
8
201(g) of the Federal Food, Drug, and Cosmetic 
9
Act, that is subject to section 503(b)(1) of such 
10
Act.’’. 
11
(3) UNINSURED INDIVIDUALS.— 
12
(A) IN GENERAL.—Beginning on and after 
13
January 1, 2022, a pharmacy shall provide to 
14
any individual who has diabetes and is not en-
15
rolled in any health plan access to an insulin 
16
drug at the average net price for such drug 
17
published pursuant to subsection (a), plus the 
18
average charges for the distribution and dis-
19
pensing described in subparagraph (C) for such 
20
drug. 
21
(B) REVIEW
OF
CHARGES.—Beginning 
22
January 1, 2023, and annually thereafter, the 
23
Inspector General of the Department of Health 
24
and Human Services shall review the amount of 
25
01:44 Aug 10, 2021
H4813
10 
•HR 4813 IH
charges paid by an individual described in sub-
1
paragraph (A) and submit to Congress a report 
2
on such review. 
3
(C) CHARGES FOR DISTRIBUTING AND DIS-
4
PENSING.—For purposes of subparagraph (A), 
5
charges for distribution and dispensing de-
6
scribed in this subsection— 
7
(i) are charges associated with the 
8
transactions, with respect to an insulin 
9
drug, between wholesalers, distributors, re-
10
tailers, and pharmacies; and 
11
(ii) may not exceed 10 percent of the 
12
average net price of such an insulin drug. 
13
(D) DEFINITIONS.—In this section: 
14
(i) INSULIN.— 
15
(I) IN GENERAL.—The term ‘‘in-
16
sulin’’ means a prescription drug con-
17
taining insulin that is approved by the 
18
Food and Drug Administration to im-
19
prove glycemic control in patients with 
20
diabetes mellitus (and may include 
21
any medical supplies included with 
22
such drug or associated with the in-
23
jection of such drug). 
24
01:44 Aug 10, 2021
H4813
11 
•HR 4813 IH
(II) 
EXCLUSION.—Such 
term 
1
does not include any medical supplies 
2
that provides for the monitoring of in-
3
sulin levels. 
4
(ii) LIST
PRICE.—The term ‘‘list 
5
price’’ has the meaning given the term 
6
wholesale 
acquisition 
cost 
in 
section 
7
1847A(c)(6)(B) of the Social Security Act 
8
(42 U.S.C. 1395w–3a(c)(6)(B)). 
9
(iii) NET
PRICE.—The term ‘‘net 
10
price’’ means, with respect to prescription 
11
drug coverage under a group health plan , 
12
the list price of the drug net all rebates, 
13
discounts, concessions, and other adjust-
14
ments applied to the cost paid by the 
15
group health plan, or by any other entity 
16
that provides pharmacy benefit manage-
17
ment services under a contract with any 
18
such group health plan, regardless of 
19
whether such adjustments are prospective 
20
or retrospective. 
21
(iv) PRESCRIPTION DRUG.—The term 
22
‘‘prescription drug’’ mean a drug, as de-
23
fined in section 201(g) of the Federal 
24
Food, Drug, and Cosmetic Act (21 U.S.C. 
25
01:44 Aug 10, 2021
H4813
12 
•HR 4813 IH
321(g)), 
that 
is 
subject 
to 
section 
1
503(b)(1) 
of 
such 
Act 
(21 
U.S.C. 
2
353(b)(1)). 
3
Æ 
01:44 Aug 10, 2021
H4813
